$2.54T
Total marketcap
$185B
Total volume
BTC 50.09%     ETH 15.88%
Dominance

Immunocore IMCR Stock

60.49 USD {{ price }} -0.558935% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
3.01B USD
LOW - HIGH [24H]
59.6 - 61.37 USD
VOLUME [24H]
552.53K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.44 USD

Immunocore Price Chart

Immunocore IMCR Financial and Trading Overview

Immunocore stock price 60.49 USD
Previous Close 57.76 USD
Open 57.75 USD
Bid 0 USD x 2900
Ask 0 USD x 900
Day's Range 56.46 - 58.5 USD
52 Week Range 29.16 - 69.06 USD
Volume 152.19K USD
Avg. Volume 256.77K USD
Market Cap 2.68B USD
Beta (5Y Monthly) 0.575598
PE Ratio (TTM) N/A
EPS (TTM) -1.44 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 81.62 USD

IMCR Valuation Measures

Enterprise Value 2.53B USD
Trailing P/E N/A
Forward P/E -36.904457
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 16.15334
Price/Book (mrq) 10.227714
Enterprise Value/Revenue 15.229
Enterprise Value/EBITDA -68.94

Trading Information

Immunocore Stock Price History

Beta (5Y Monthly) 0.575598
52-Week Change 74.88%
S&P500 52-Week Change 20.43%
52 Week High 69.06 USD
52 Week Low 29.16 USD
50-Day Moving Average 57.07 USD
200-Day Moving Average 55.27 USD

IMCR Share Statistics

Avg. Volume (3 month) 256.77K USD
Avg. Daily Volume (10-Days) 225.79K USD
Shares Outstanding 46.23M
Float 27.99M
Short Ratio 9.78
% Held by Insiders 14.68%
% Held by Institutions 69.28%
Shares Short 2.69M
Short % of Float N/A
Short % of Shares Outstanding 5.82%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -25.20%
Operating Margin (ttm) -24.44%
Gross Margin 40.03%
EBITDA Margin -22.089%

Management Effectiveness

Return on Assets (ttm) -7.11%
Return on Equity (ttm) -19.10%

Income Statement

Revenue (ttm) 165.8M USD
Revenue Per Share (ttm) 3.54 USD
Quarterly Revenue Growth (yoy) 98.20%
Gross Profit (ttm) 54.11M USD
EBITDA -36627000 USD
Net Income Avi to Common (ttm) -41793000 USD
Diluted EPS (ttm) -1.1
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 337.46M USD
Total Cash Per Share (mrq) 6.98 USD
Total Debt (mrq) 68.14M USD
Total Debt/Equity (mrq) 24.86 USD
Current Ratio (mrq) 4.558
Book Value Per Share (mrq) 5.665

Cash Flow Statement

Operating Cash Flow (ttm) 13.73M USD
Levered Free Cash Flow (ttm) 18.34M USD

Profile of Immunocore

Country United States
State N/A
City Abingdon
Address 92 Park Drive
ZIP OX14 4RY
Phone 44 12 3543 8600
Website https://www.immunocore.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 408

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Q&A For Immunocore Stock

What is a current IMCR stock price?

Immunocore IMCR stock price today per share is 60.49 USD.

How to purchase Immunocore stock?

You can buy IMCR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Immunocore?

The stock symbol or ticker of Immunocore is IMCR.

Which industry does the Immunocore company belong to?

The Immunocore industry is Biotechnology.

How many shares does Immunocore have in circulation?

The max supply of Immunocore shares is 49.82M.

What is Immunocore Price to Earnings Ratio (PE Ratio)?

Immunocore PE Ratio is now.

What was Immunocore earnings per share over the trailing 12 months (TTM)?

Immunocore EPS is -1.44 USD over the trailing 12 months.

Which sector does the Immunocore company belong to?

The Immunocore sector is Healthcare.

Immunocore IMCR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD